Clinical Cancer Research, Vol 4, Issue 12 3005-3010, Copyright © 1998 by American Association for Cancer Research

ARTICLES

PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics

JI Risinger, K Hayes, GL Maxwell, ME Carney, RK Dodge, JC Barrett and A Berchuck
Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.

Mutation of the PTEN tumor suppressor gene is a frequent event in endometrial cancers. In other types of cancers, PTEN mutation has been associated with metastatic behavior and advanced stage. To examine the relationship between PTEN mutation and clinical features of endometrial cancers, we screened 136 cases for mutations in the nine exons and intronic splice sites of the PTEN gene, using single-strand conformation analysis, and aberrant bands were sequenced. Mutations were noted in 44 of 136 (32%) endometrial cancers, and two mutations were present in 8 cases. There were 36 cases with mutations resulting in truncated protein products, 6 cases with missense mutations in the phosphatase domain, 1 case with an in-frame deletion, and 1 case with a large insertion. Mutation of the PTEN gene correlated most closely with endometrioid histology; mutations were seen in only 5% (1 of 21) of serous/clear cell cancers compared with 37% (43 of 115) of endometrioid cancers (P = 0.004). PTEN mutation was associated with early stage, nonmetastatic disease and more favorable survival in both the entire group of 136 cases and in the 115 endometrioid cases. In addition, PTEN mutation correlated with other molecular features associated with favorable clinical behavior, including microsatellite instability and absence of p53 overexpression. Microsatellite instability was found in 60% of cases with PTEN mutations compared with only 25% of cases without mutations (P = 0.004). Overexpression of p53 was seen in only 14% of cases with PTEN mutations compared to 39% of cases without mutations (P = 0.006). In conclusion, PTEN mutation is associated with endometrioid histology and other favorable pathological, clinical, and molecular features rather than with increased metastatic potential as has been noted in some other types of cancers.

This article has been cited by other articles:

				J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney, R. Baumber, R. Parsons, K. R. Lamborn, M. S. Berger, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro-oncol, July 1, 2007; 9(3): 271 - 279. [Abstract] [Full Text] [PDF]

				J J Brosens and B Gellersen Death or survival - progesterone-dependent cell fate decisions in the human endometrial stroma. J. Mol. Endocrinol., June 1, 2006; 36(3): 389 - 398. [Abstract] [Full Text] [PDF]

				D. Black, R. A. Soslow, D. A. Levine, C. Tornos, S. C. Chen, A. J. Hummer, F. Bogomolniy, N. Olvera, R. R. Barakat, and J. Boyd Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma J. Clin. Oncol., April 10, 2006; 24(11): 1745 - 1753. [Abstract] [Full Text] [PDF]

				M. A. Bidus, J. I. Risinger, G. V.R. Chandramouli, L. A. Dainty, T. J. Litzi, A. Berchuck, J. C. Barrett, and G. L. Maxwell Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray Clin. Cancer Res., January 1, 2006; 12(1): 83 - 88. [Abstract] [Full Text] [PDF]

				G. L. Maxwell, G.V.R. Chandramouli, L. Dainty, T. J. Litzi, A. Berchuck, J. C. Barrett, and J. I. Risinger Microarray Analysis of Endometrial Carcinomas and Mixed Mullerian Tumors Reveals Distinct Gene Expression Profiles Associated with Different Histologic Types of Uterine Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4056 - 4066. [Abstract] [Full Text] [PDF]

				I. Sansal and W. R. Sellers The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway J. Clin. Oncol., July 15, 2004; 22(14): 2954 - 2963. [Abstract] [Full Text] [PDF]

				F.-S. Liu, J.-T. Dong, J.-T. Chen, Y.-T. Hsieh, E. S.-C. Ho, M.-J. Hung, C.-H. Lu, and L.-C. Chiou KAI1 Metastasis Suppressor Protein Is Down-Regulated during the Progression of Human Endometrial Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1393 - 1398. [Abstract] [Full Text] [PDF]

				Y. Saga, H. Mizukami, M. Suzuki, T. Kohno, M. Urabe, K. Ozawa, and I. Sato Overexpression of PTEN Increases Sensitivity to SN-38, an Active Metabolite of the Topoisomerase I Inhibitor Irinotecan, in Ovarian Cancer Cells Clin. Cancer Res., May 1, 2002; 8(5): 1248 - 1252. [Abstract] [Full Text] [PDF]

				H. Wang, W. Douglas, M. Lia, W. Edelmann, R. Kucherlapati, K. Podsypanina, R. Parsons, and L. H. Ellenson DNA Mismatch Repair Deficiency Accelerates Endometrial Tumorigenesis in Pten Heterozygous Mice Am. J. Pathol., April 1, 2002; 160(4): 1481 - 1486. [Abstract] [Full Text] [PDF]

				X.-P. Zhou, S. Kuismanen, M. Nystrom-Lahti, P. Peltomaki, and C. Eng Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors Hum. Mol. Genet., February 1, 2002; 11(4): 445 - 450. [Abstract] [Full Text] [PDF]

				T. Minaguchi, H. Yoshikawa, K. Oda, T. Ishino, T. Yasugi, T. Onda, S. Nakagawa, K. Matsumoto, K. Kawana, and Y. Taketani PTEN Mutation Located Only Outside Exons 5, 6, and 7 Is an Independent Predictor of Favorable Survival in Endometrial Carcinomas Clin. Cancer Res., September 1, 2001; 7(9): 2636 - 2642. [Abstract] [Full Text] [PDF]

				H. Sasaki, M. C. Zlatescu, R. A. Betensky, Y. Ino, J. G. Cairncross, and D. N. Louis PTEN Is a Target of Chromosome 10q Loss in Anaplastic Oligodendrogliomas and PTEN Alterations Are Associated with Poor Prognosis Am. J. Pathol., July 1, 2001; 159(1): 359 - 367. [Abstract] [Full Text] [PDF]

				G. L. Mutter PTEN, a Protean Tumor Suppressor Am. J. Pathol., June 1, 2001; 158(6): 1895 - 1898. [Full Text] [PDF]

				G. L. MAXWELL, J. I. RISINGER, A. A. ALVAREZ, J. C. BARRETT, and A. BERCHUCK Favorable Survival Associated With Microsatellite Instability in Endometrioid Endometrial Cancers Obstet. Gynecol., March 1, 2001; 97(3): 417 - 422. [Abstract] [Full Text] [PDF]

				N. Sato, H. Tsunoda, M. Nishida, Y. Morishita, Y. Takimoto, T. Kubo, and M. Noguchi Loss of Heterozygosity on 10q23.3 and Mutation of the Tumor Suppressor Gene PTEN in Benign Endometrial Cyst of the Ovary: Possible Sequence Progression from Benign Endometrial Cyst to Endometrioid Carcinoma and Clear Cell Carcinoma of the Ovary Cancer Res., December 1, 2000; 60(24): 7052 - 7056. [Abstract] [Full Text]

				H. B. Salvesen, N. MacDonald, A. Ryan, O. E. Iversen, I. J. Jacobs, L. A. Akslen, and S. Das Methylation of hMLH1 in a Population-based Series of Endometrial Carcinomas Clin. Cancer Res., September 1, 2000; 6(9): 3607 - 3613. [Abstract] [Full Text]

				G. L. Maxwell, J. I. Risinger, K. A. Hayes, A. A. Alvarez, R. K. Dodge, J. C. Barrett, and A. Berchuck Racial Disparity in the Frequency of PTEN Mutations, but not Microsatellite Instability, in Advanced Endometrial Cancers Clin. Cancer Res., August 1, 2000; 6(8): 2999 - 3005. [Abstract] [Full Text]

				V. Stambolic, M.-S. Tsao, D. Macpherson, A. Suzuki, W. B. Chapman, and T. W. Mak High Incidence of Breast and Endometrial Neoplasia Resembling Human Cowden Syndrome in pten+/- Mice Cancer Res., July 1, 2000; 60(13): 3605 - 3611. [Abstract] [Full Text]

				I. U. Ali, L. M. Schriml, and M. Dean Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity J Natl Cancer Inst, November 17, 1999; 91(22): 1922 - 1932. [Abstract] [Full Text] [PDF]

				M. Hahn, I. Wieland, O. N. Koufaki, H. Gorgens, S. B. Sobottka, G. Schackert, and H. K. Schackert Genetic Alterations of the Tumor Suppressor Gene PTEN/MMAC1 in Human Brain Metastases Clin. Cancer Res., September 1, 1999; 5(9): 2431 - 2437. [Abstract] [Full Text] [PDF]